Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118551 | 0.90 | CHKA (0.36) | CHKARENEGLN1SLC6A2SLC6A4 | |
| SCHEMBL4110744 | 0.86 | CHKA (0.34) | CHKARENEGLN1SLC6A2SLC6A4 | |
| SCHEMBL4114006 | 0.83 | HTR2A (0.38) | RENSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4109317 | 0.80 | CYP1A2 (0.40) | CHKARENSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4107635 | 0.80 | NR4A2 (0.40) | CHKARENSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4098264 | 0.73 | LMNA (0.35) | RENSLC6A2SLC6A4KCNH2 | |
| SCHEMBL4106037 | 0.69 | MEN1 (0.36) | RENSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4111663 | 0.69 | SLC6A4 (0.37) | RENSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4021110 | 0.69 | HTR2A (0.35) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL10475757 | 0.67 | HTR1A (0.35) | CHKASLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | CHKA 1882/4885REN 788/4885EGLN1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.